Oxford, UK, 07 Sep 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced the European Patent Office (EPO) has announced its intention…
Oxford, UK, 16th January 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that the Thames Valley Cancer SCN Project has awarded…
Oxford, UK, 29th August 2014 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced an agreement with Daiichi-Sankyo for biomarker discovery, with the…
Oxford, UK, 24 July 2014 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that the United States patent for its biomarker platform…
Oxford, UK, 15th April 2013 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced an agreement with AstraZeneca for biomarker discovery, with the…
Oxford, UK, 16 October 2013 Oxford Cancer Biomarkers has appointed David Oxlade as Chairman, a key growth milestone for the company which aims to benefit cancer patients through development of tests that allow medicines to be personalised. Founded by Nick…
Oxford Cancer Biomarkers has appointed Nick McCooke as CEO, a key growth milestone for the company which aims to benefit cancer patients through development of tests that allow medicines to be personalised. Founded by Nick La Thangue, Ph.D., Chair of…
Professors David Kerr and Nick La Thangue offer oncology consulting and biomarker R&D activities spun out from the University of Oxford OXFORD, U.K. and RESEARCH TRIANGLE PARK, N.C. – January 18, 2012 – Continuing its commitment to advancing personalized medicine…